Ulcerative colitis is the most common type of
inflammatory bowel disease that affects the colon (lining of the
large intestine) and rectum. The inflammation produces tiny sores
called ulcers. These disease can affect people of any age, though
prevalence is especially high among people under 30 years of age. The
major symptoms of this disease are diarrhea, belly pain/cramps,
bleeding from the rectum, also other indications are sudden and
unexplained weight loss, loss of appetite, joint pain, eye disease,
thickening of the intestinal wall, blood infection (sepsis), kidney
stones and liver disease. The diagnosis of this disease can be
carried out by physical examination using tests such as colonoscopy,
endoscopy, biopsy, CT scan and blood test.
If ulcerative colitis persists for over 8 years or
longer, it may lead to colon cancer. The people having mild symptoms
of this disease can be cured by over the counter drugs such as
Imodium therapy. However, transcription medicine such as steroid
medicines and amino salicylates are widely used to treat the
condition. In severe cases, the patient may need to undergo surgery
to remove the colon, which also helps prevent colon cancer.
Fill the form for an exclusive sample of this
report :
https://www.coherentmarketinsights.com/insight/request-sample/238
Also, some genetically engineered drugs also used
to treat ulcerative colitis. These drugs are made up of certain
living organisms that help suppress the inflammation, by targeting
the inflammatory proteins such as cytokines. Some genetically
engineered drugs approved by the U.S. FDA for treatment of the
condition are Adalimumab (Humira), Golimumab (Simponi), Infliximab
(Remicade) and Vedolizumab (Entyvio).
These genetically engineered drugs may show some
side effects such as fever, headache, hives, low blood pressure,
breathing difficulties, back pain, and stomach pain. Also, these
drugs may affect the immunity power of body to fight infection.
The exact cause for ulcerative colitis is unknown,
though possible reasons are may be genetic factors, environmental
changes, or weakened immune system. The ulcerative colitis can be
prevented by simple healthy habits such as eating small meals
throughout the day, staying well hydrated throughout the day,
avoiding fatty foods, and limiting intake of high-fiber food.
According to data released by the Centers for
Disease Control and Prevention (CDC), there are around 2.2 to 14.3
cases found per 100,000 population per year. Also, according to a
study conducted in 2014 by Crohn’s & Colitis Foundation of
America (CCFA), 907,000 people suffered from ulcerative colitis in
the U.S. (data based on the research conducted in between 2011-2014
by CCFA)
Ulcerative colitis market taxonomy:
Global Market by Drug Type
-
Infliximab
-
Golimumab
-
Adalimumab
-
Vedolizumab
-
Mesalamine
-
Budesonide
-
Balsazide
Global Market by Dosage Form
-
Parenteral
-
Oral
Global Market by Geography
-
North America
-
Europe
-
APAC
-
Latin America
-
Middle East
-
Africa
High prevalence in developed regions and
increasing incidence rate in emerging economies will play major role
in driving growth of the ulcerative colitis market
According to the study of CCFA, industrialized
countries have highest incidence rate for ulcerative colitis. This
disease is most prevalent in urban areas than in rural areas, also it
can affect to any age group of people but most cases diagnosed are of
the age in between 15 to 35. According the stats of World
Gastroenterology Organization (WGO), there is rising incidence rate
in emerging economies such as India. Due to changing diet and
lifestyle pattern, the emerging economies will show high growth rate
in incidence rate of ulcerative colitis in the near future.
According to data collected from various sources
and compiled by Coherent Market Insights, Europe have the highest
annual rate of incidence worldwide, followed by North America and the
lowest in Asia and Middle East.
However, North America holds the largest share in
the global ulcerative colitis market due to continuous improvements
in drugs, increased uptake of medicines, awareness about treatment
and increasing clinical research. APAC region will show high growth
in ulcerative colitis market during forecast years (2017-2024), due
to raising awareness about the treatment, changing lifestyle will
cause to increase prevalence and incidence rate, entry of new drugs
in the market also some companies losing their patent of ulcerative
drugs in coming years, like Humira (adalimumab) lost its patent in
2016 and Remicade will lose its patent in 2018. Also, some drugs
companies have launched their biosimilar drugs in ulcerative colitis
industry. For example, in 2016, India-based Torrent Pharmaceuticals
launched a biosimilar drug under the brand name Adfra to compete
Humira. Humira is a trade name for adalimumab medication owned by
AbbVie Inc.
Request to view table of content @
https://www.coherentmarketinsights.com/ongoing-insight/toc/238
Some major companies playing leading role in
ulcerative colitis market are AbbVie Inc., Hospira, Celltrion
Healthcare, Johnson and Johnson, F. Hoffmann-La Roche AG, Warner
Chilcott, Janssen Pharmaceuticals Inc. and Takeda Pharmaceuticals
Company Ltd.
Some leading drugs are used to reduce inflammation
and swelling and to cure ulcerative colitis are include Sulfasalazine
(Azulfidine), Mesalamine (Asacol and Lialda), Balsalazide (Colazal),
and Olsalazine (Dipentum), Inflectra, Remsima, Adalimumab (Humira),
Infliximab (Remicade).
About Coherent Market Insights:
Coherent Market Insights is a
prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations
related to emerging market trends, technologies, and potential
absolute dollar opportunity
No comments:
Post a Comment